GLP1R and type 2 diabetes mellitus: For instance, a meta-analysis of randomized, controlled trials involving 63 594 patients with T2D indicated that treatment with albiglutide (a GLP-1 agonist) was associated with a 24% reduction of all sites of cancer when compared to the placebo group [6].